High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	Stanford University National Institutes of Health (NIH)
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00186394

Purpose

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

Condition	Intervention	Phase
Lymphoma, Non-Hodgkin	Procedure: ablative allogeneic hematopoietic cell transplantation	Phase II

MedlinePlus related topics: Lymphoma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma

Further study details as provided by Stanford University:

Primary Outcome Measures:

Safety
Toxicity
Efficacy

Secondary Outcome Measures:

Incidence of acute and chronic GVHD

Estimated Enrollment:	35
Study Start Date:	April 2000

Detailed Description:

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

Eligibility

Ages Eligible for Study:	18 Years to 61 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma

Age: >18 and <61 years of age

Signed informed consent
 Exclusion Criteria:Hepatic dysfunction defined by serum transaminases >2.5X normal values

Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min

Diseases other than non-Hodgkin's lymphoma

Prior bone marrow transplant procedure

Severe psychological or medical illness

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186394

Locations

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

National Institutes of Health (NIH)

Investigators

Principal Investigator:

Wen-Kai Weng

Stanford University

More Information

Study ID Numbers:	BMT4L, 76679, BMT4L, NCT00186394
Study First Received:	September 13, 2005
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00186394
Health Authority:	USA:IRB

Study placed in the following topic categories:

Lymphatic Diseases
Immunoproliferative Disorders
Lymphoma, small cleaved-cell, diffuse

Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin
Lymphoma

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on January 15, 2009